The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer.

Por Hubert, A, Peretz, T, Manor, O, Kaduri, L, Wienberg, N, Lerer, I, Sagi, M, Abeliovich, D
Publicado em 1999

The 8765delAG mutation in BRCA2 is common among Jews of Yemenite extraction.

Por Lerer, I, Wang, T, Peretz, T, Sagi, M, Kaduri, L, Orr-Urtreger, A, Stadler, J, Gutman, H, Abeliovich, D
Publicado em 1998

The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.

Por Abeliovich, D, Kaduri, L, Lerer, I, Weinberg, N, Amir, G, Sagi, M, Zlotogora, J, Heching, N, Peretz, T
Publicado em 1997

Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma

Por Lotem, M, Shiloni, E, Pappo, I, Drize, O, Hamburger, T, Weitzen, R, Isacson, R, Kaduri, L, Merims, S, Frankenburg, S, Peretz, T
Publicado em 2004